

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Kinneret SAVITZKY et al. Conf.:
Appl. No.: New Group:
Filed: February 28, 2002 Examiner:
For: VARIANT OF TNF-RECEPTOR



INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Assistant Commissioner for Patents
Washington, DC 20231

February 28, 2002

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).
09/599,400

U.S. Filing Date(s)
June 22, 2000

III. FEES


This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 

Marc S. Weiner, #32,181


MSW/CAM/gh
2786-0207P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Enclosures: ☒ PTO-1449
☐ References
☐ Foreign Search Report
☐ Other:

(Rev. 11/02/01)

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

 ATTY DOCKET NO.
2786-0207P

 APPLICATION NO.
Div of
09/599,400

 APPLICANT
Kinneret SAVITZKY et al.

 FILING DATE
February 28, 2002

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

J1050 U.S. PTO
 10/084705
 02/28/02

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

	Weinshenker et al., Genetic Variants in the tumor necrosis factor receptor 1 gene in patients with MS. 1999, Neurology, vol. 22, pages 1500-1503.
	Michael J.. A soluble form of CD 137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sea of patients with rheumatoid arthritis. 1998, Eur. J. Immunol. Vol. 28, pages 290-295.
	Fuchs et al. Structure of the human TNF receptor 1 (p60) gne (TNFR1) and localization to chromosome 12p13, 1992, Genomics, Vol. 13, pages 219-224.
	Mikayama et al. Proc. Natl. Acad. Sci. USA Vol. 90, pages 10056-10060. Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor.
	Voet et al. Biochemistry, John Wiley & Sons, Inc. pages 126-128 and 228-234.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.